PubRank

Shaker A Mousa

Author PubWeight™ 114.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 2011 2.79
2 Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease. Saudi J Kidney Dis Transpl 2015 1.96
3 Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009 1.56
4 Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 2012 1.44
5 L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009 1.43
6 Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009 1.40
7 Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004 1.28
8 Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem 2011 1.28
9 Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood 2003 1.27
10 Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006 1.25
11 Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine 2009 1.25
12 Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010 1.22
13 Emerging nanopharmaceuticals. Nanomedicine 2008 1.21
14 Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003 1.21
15 Metformin and neoplasia: implications and indications. Pharmacol Ther 2011 1.20
16 Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007 1.18
17 The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007 1.17
18 Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules 2009 1.12
19 Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 2011 1.12
20 High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012 1.12
21 Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology 2009 1.08
22 Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res 2003 1.07
23 Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Lett 2007 1.07
24 Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop 2011 1.05
25 PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 2008 1.04
26 Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol 2013 1.03
27 Thyroid hormone and angiogenesis. Vascul Pharmacol 2009 1.00
28 Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol 2009 1.00
29 Current status and future directions in the management of chronic hepatitis C. Virol J 2012 0.99
30 The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002 0.97
31 Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. J Cell Biochem 2006 0.96
32 Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One 2011 0.96
33 Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009 0.96
34 Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 2014 0.96
35 Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res 2010 0.95
36 Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol 2004 0.95
37 Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2013 0.95
38 Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 2008 0.94
39 Green tea modulates reserpine toxicity in animal models. J Toxicol Sci 2009 0.93
40 Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol 2012 0.93
41 Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta 2008 0.92
42 Biosensors: the new wave in cancer diagnosis. Nanotechnol Sci Appl 2010 0.92
43 The Effects of EPA+DHA and Aspirin on Inflammatory Cytokines and Angiogenesis Factors. World J Cardiovasc Dis 2011 0.91
44 Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther 2007 0.91
45 Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol Disord Drug Targets 2009 0.90
46 Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med 2011 0.90
47 Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002 0.89
48 Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids 2011 0.89
49 Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 2011 0.89
50 Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone. Thyroid 2013 0.88
51 Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 2010 0.88
52 Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol 2009 0.88
53 Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease. Cardiol J 2011 0.88
54 Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers (Basel) 2011 0.87
55 Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res 2011 0.86
56 The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol 2009 0.86
57 Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutr Cancer 2005 0.86
58 Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2008 0.85
59 Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 2008 0.85
60 Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag 2010 0.85
61 Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior. Horm Cancer 2013 0.84
62 Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int 2011 0.83
63 The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res 2009 0.83
64 Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy. J Womens Health (Larchmt) 2005 0.83
65 Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol 2002 0.83
66 Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer 2013 0.82
67 The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 2009 0.82
68 Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol Behav 2009 0.82
69 Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (Lond) 2013 0.82
70 Micro- and nanoparticle-based vaccines for hepatitis B. Adv Exp Med Biol 2007 0.82
71 Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone. FASEB J 2013 0.82
72 Evaluation of platelet antagonists in in vitro flow models of thrombosis. Methods Mol Med 2004 0.82
73 Treatment options for diabetes: potential role of stem cells. Diabetes Res Clin Pract 2012 0.82
74 Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps. Discov Med 2012 0.81
75 The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. Pharmgenomics Pers Med 2009 0.81
76 The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. Prostaglandins Leukot Essent Fatty Acids 2012 0.81
77 Molecular basis for certain neuroprotective effects of thyroid hormone. Front Mol Neurosci 2011 0.81
78 Prevention strategies for antimicrobial resistance: a systematic review of the literature. Infect Drug Resist 2010 0.81
79 Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmgenomics Pers Med 2009 0.81
80 Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis 2010 0.81
81 Current status of nucleoside antivirals in chronic hepatitis B. Drugs Today (Barc) 2009 0.81
82 Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder. Drug Healthc Patient Saf 2009 0.81
83 Potential role of naturally derived polyphenols and their nanotechnology delivery in cancer. Mol Biotechnol 2013 0.80
84 Fibrin and collagen differentially but synergistically regulate sprout angiogenesis of human dermal microvascular endothelial cells in 3-dimensional matrix. Int J Cell Biol 2013 0.80
85 The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012 0.80
86 Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway. Aging Cell 2008 0.80
87 Inhibition property of green tea extract in relation to reserpine-induced ribosomal strips of rough endoplasmic reticulum (rER) of the rat kidney proximal tubule cells. J Toxicol Sci 2009 0.80
88 Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol 2010 0.80
89 Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydr Res 2009 0.80
90 Heparin-cellulose-charcoal composites for drug detoxification prepared using room temperature ionic liquids. Chem Commun (Camb) 2008 0.79
91 Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer. Pharm Res 2015 0.79
92 Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. Adv Urol 2009 0.79
93 Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit Rev Food Sci Nutr 2010 0.79
94 Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine 2008 0.79
95 Current therapies and new strategies for the management of Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010 0.79
96 Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis 2013 0.79
97 The antiplatelet activity of camel urine. J Altern Complement Med 2011 0.79
98 Thyroid hormone-induced angiogenesis. Curr Cardiol Rev 2009 0.78
99 Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model. Nutr Cancer 2005 0.78
100 Analysis of fine structure and biochemical changes of retina during aging of Wistar albino rats. Clin Experiment Ophthalmol 2013 0.78
101 Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications. Curr Opin Investig Drugs 2010 0.78
102 Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine 2013 0.78
103 The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med 2012 0.78
104 Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag 2008 0.78
105 Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. Blood Coagul Fibrinolysis 2007 0.78
106 The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol 2008 0.78
107 Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis 2012 0.77
108 Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. Curr Pharm Des 2011 0.77
109 Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med 2010 0.77
110 Chronic pulsatile shear stress impacts synthesis of proteoglycans by endothelial cells: effect on platelet aggregation and coagulation. J Cell Biochem 2002 0.77
111 Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol Vis 2012 0.77
112 Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. J Cell Biochem 2007 0.77
113 OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis. Cancer Lett 2013 0.76
114 Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA). Clin Appl Thromb Hemost 2009 0.76
115 Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model. Antimicrob Agents Chemother 2012 0.76
116 Mayer-Rokitansky-Kuster-Hauser syndrome: complications, diagnosis and possible treatment options: a review. Gynecol Endocrinol 2014 0.76
117 Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. Endocr Res 2013 0.76
118 Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Methods Mol Med 2004 0.76
119 Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg Med Chem Lett 2004 0.76
120 Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res 2009 0.76
121 Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther 2009 0.75
122 High Density Lipoprotein (HDL) Modulation Targets. Drugs Future 2010 0.75
123 Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine. Pharmgenomics Pers Med 2009 0.75
124 Pharmacogenomics in osteoporosis: Steps toward personalized medicine. Pharmgenomics Pers Med 2009 0.75
125 Antiplatelet, anticoagulant, and thrombolytic drug interactions. Methods Mol Med 2004 0.75
126 Stem cells in the management of heart failure: what have we learned from clinical trials? Expert Rev Cardiovasc Ther 2014 0.75
127 The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand. Appl Health Econ Health Policy 2008 0.75
128 Current status and future direction in the management of malignant melanoma. Melanoma Res 2017 0.75
129 Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series. Clin Appl Thromb Hemost 2007 0.75
130 Onyx® in the management of cranial arteriovenous malformations. Expert Rev Med Devices 2013 0.75
131 The future of anticoagulant therapy. Cardiovasc Ther 2011 0.75
132 Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opin Pharmacother 2008 0.75
133 Semisynthesis and pharmacological activities of thyroxine analogs: Development of new angiogenesis modulators. Bioorg Med Chem Lett 2010 0.75
134 Angiogenesis, choroidal neovascularization, and the coagulation system. Retina 2005 0.75
135 Novel in vitro perfusion model to study the interaction between coagulation and blood-borne metastasis. J Cell Biochem 2005 0.75
136 Hybrid polymeric nanoparticles: potential candidate for ophthalmic delivery. Methods Mol Biol 2013 0.75
137 Correction: Novel leptin OB3 peptide-induced signaling and progression in thyroid cancers: Comparison with leptin. Oncotarget 2017 0.75
138 Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators. Bioorg Med Chem Lett 2009 0.75
139 Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: new anti-angiogenesis analogs. J Enzyme Inhib Med Chem 2011 0.75
140 Effect of Green Tea Extract Encapsulated Into Chitosan Nanoparticles on Hepatic Fibrosis Collagen Fibers Assessed by Atomic Force Microscopy in Rat Hepatic Fibrosis Model. J Nanosci Nanotechnol 2015 0.75
141 Relevance of nanotechnology in modulating oxidative stress: an overview. Methods Mol Biol 2013 0.75
142 Quantification of the Healing Effect in Hepatic Fibrosis Induced by Chitosan Nano-Encapsulated Green Tea in Rat Model. J Nanosci Nanotechnol 2015 0.75